COPD Exacerbation

A COPD exacerbation is an acute worsening of respiratory symptoms beyond normal day-to-day variation that requires a change in medication. The Anthonisen criteria describe three cardinal symptoms: increased dyspnea, increased sputum volume, and increased sputum purulence. A Type 1 exacerbation has all three; Type 2 has two; Type 3 has one plus a minor criterion (upper respiratory infection in the past 5 days, fever without other cause, increased wheezing, increased cough, or a 20% increase in respiratory rate or heart rate).

Approximately 70–80% of exacerbations are triggered by respiratory infections — most commonly viral (rhinovirus, influenza, RSV, coronavirus) and less commonly bacterial (Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Pseudomonas aeruginosa in severe COPD). The remaining 20–30% are triggered by non-infectious causes: air pollution, cold air, cardiac decompensation, pulmonary embolism, or pneumothorax.

Identifying the trigger matters because it determines treatment. An exacerbation triggered by PE will not respond to bronchodilators and antibiotics — and the underlying PE will worsen. An exacerbation triggered by cardiac decompensation requires diuresis, not just bronchodilators. The clinical assessment must go beyond confirming the COPD diagnosis and actively consider competing or contributing causes.

Antibiotics benefit patients with Type 1 exacerbations (all three cardinal symptoms) and patients requiring mechanical ventilation. The evidence for antibiotic benefit in Type 2 and Type 3 exacerbations is weaker, and antibiotics are not recommended for exacerbations without increased sputum purulence in most guidelines.

Among the three Anthonisen criteria, purulent sputum is the strongest predictor of bacterial infection and the best indicator for antibiotic benefit. Purulence reflects neutrophil-derived myeloperoxidase — it is a reliable marker of bacterial load. Increased dyspnea and sputum volume without purulence have much lower predictive value for bacterial infection.

Antibiotic selection should be guided by severity and local resistance patterns. For mild-to-moderate exacerbations, amoxicillin-clavulanate, azithromycin, or doxycycline are appropriate first-line options. For severe exacerbations or patients with risk factors for Pseudomonas (frequent exacerbations, recent hospitalization, prior Pseudomonas isolation, severe underlying COPD), broader coverage is needed. Fluoroquinolones (levofloxacin, moxifloxacin) provide Pseudomonas coverage and are appropriate in this setting.

Procalcitonin can help guide antibiotic decisions in COPD exacerbations — a low procalcitonin (below 0.1 ng/mL) suggests a viral or non-infectious trigger and supports withholding antibiotics. However, procalcitonin is not universally available and should be used as one data point alongside clinical assessment, not as a standalone decision rule.

Short-acting bronchodilators are the foundation of acute COPD exacerbation management. Short-acting beta-2 agonists (albuterol, levalbuterol) and short-acting anticholinergics (ipratropium) are used together — combination therapy provides greater bronchodilation than either agent alone. Nebulized delivery is preferred in moderate-to-severe exacerbations; metered-dose inhaler with spacer is equivalent in mild exacerbations.

Systemic corticosteroids shorten exacerbation duration, reduce treatment failure, and improve lung function. Prednisone 40 mg daily for 5 days is the standard regimen — the REDUCE trial demonstrated that 5 days is as effective as 14 days with fewer adverse effects. Longer courses increase the risk of hyperglycemia, adrenal suppression, and other steroid-related complications without additional benefit.

Methylxanthines (theophylline, aminophylline) are not recommended in acute COPD exacerbations — they provide minimal additional bronchodilation over beta-2 agonists and anticholinergics, and their narrow therapeutic window and drug interactions make them more hazardous than beneficial in the acute setting.

Oxygen therapy in COPD exacerbation requires careful titration. The target SpO2 is 88–92% — not the 94–98% target used in most other clinical settings. This distinction is critical and frequently misapplied.

In patients with chronic hypercapnia (type 2 respiratory failure), the respiratory drive shifts from the normal CO2-based drive to a hypoxic drive. Administering high-flow oxygen suppresses this hypoxic drive and worsens hypercapnia through two mechanisms: reduced hypoxic ventilatory drive and worsening V/Q mismatch (oxygen reverses hypoxic pulmonary vasoconstriction, redirecting blood to poorly ventilated lung units). The result is rising PaCO2, respiratory acidosis, and potentially the need for intubation.

Controlled low-flow oxygen via nasal cannula (1–2 L/min) or a Venturi mask (24–28% FiO2) achieves the 88–92% target reliably. High-flow nasal cannula and non-rebreather masks are inappropriate for most COPD exacerbations because they deliver uncontrolled high FiO2.

Arterial blood gas measurement is essential in moderate-to-severe exacerbations to assess pH, PaCO2, and the degree of respiratory acidosis. A pH below 7.35 with elevated PaCO2 indicates hypercapnic respiratory failure and should prompt consideration of non-invasive ventilation.

Non-invasive ventilation (NIV, specifically BiPAP — bilevel positive airway pressure) is the most evidence-supported intervention for reducing intubation in moderate-to-severe COPD exacerbations with hypercapnic respiratory failure. The indications are: pH below 7.35 with PaCO2 above 45 mmHg, moderate-to-severe dyspnea with accessory muscle use, and respiratory rate above 25.

NIV reduces the need for intubation, reduces in-hospital mortality, reduces ICU length of stay, and reduces complications compared to standard medical therapy alone. It should be initiated early — within the first hour of presentation in appropriate patients — not as a last resort when the patient is exhausted and about to be intubated.

Contraindications to NIV include: inability to protect the airway (altered mental status, inability to cooperate), hemodynamic instability, recent facial or upper airway surgery, and copious secretions that cannot be cleared. When NIV fails — defined as worsening pH, rising PaCO2, or clinical deterioration despite 1–2 hours of NIV — intubation should not be delayed.

High-flow nasal cannula (HFNC) is an alternative for patients who cannot tolerate a BiPAP mask, but the evidence for HFNC in hypercapnic COPD exacerbation is less robust than for NIV. It is not a substitute for BiPAP in patients with significant hypercapnic respiratory failure.

Severity assessment determines whether the patient can be managed outpatient, requires hospitalization, or needs ICU-level care. Mild exacerbations — increased symptoms without significant change in vital signs, adequate oxygenation, and ability to manage at home — can often be treated outpatient with oral bronchodilators, a short course of systemic corticosteroids, and antibiotics if indicated.

Hospitalization is appropriate for: moderate-to-severe dyspnea not responding to initial treatment, SpO2 below 90% on room air, significant change in mental status, inability to manage at home, significant comorbidities (cardiac disease, pneumonia), or diagnostic uncertainty. The decision to hospitalize should also account for the patient's home support and ability to comply with outpatient treatment.

ICU admission criteria: pH below 7.35 with PaCO2 above 45 mmHg (hypercapnic respiratory failure), hemodynamic instability, altered mental status, failure of NIV, or need for intubation. Patients who meet NIV criteria should be monitored closely — those who do not improve within 1–2 hours of NIV should be considered for intubation before they deteriorate further.

The clinical exam in a COPD exacerbation: assess respiratory rate (the most sensitive vital sign for respiratory distress), accessory muscle use, paradoxical breathing, ability to speak in full sentences, and mental status. Cyanosis is a late finding. Pulsus paradoxus (blood pressure drop of more than 10 mmHg with inspiration) suggests significant air trapping.

Most patients hospitalized for COPD exacerbation improve within 3–5 days with appropriate treatment. Clinical improvement is defined by reduction in dyspnea, improvement in oxygenation, and ability to tolerate oral medications. Spirometry during an acute exacerbation is not useful — it is effort-dependent and does not guide management.

Discharge criteria: the patient should be able to use their inhaler correctly, oxygenation should be stable on their baseline supplemental oxygen (or room air if they do not use home oxygen), and they should be able to manage at home. Prescribe a short-acting bronchodilator for rescue use and ensure maintenance inhalers are optimized.

Discharge medications: complete the course of systemic corticosteroids (5 days of prednisone 40 mg is standard). Complete antibiotics if prescribed. Review and optimize maintenance inhaler therapy — LAMA (long-acting muscarinic antagonist) and LABA (long-acting beta-2 agonist) are the foundation of COPD maintenance therapy. Patients with frequent exacerbations may benefit from ICS-LABA combination therapy.

Follow-up within 4–6 weeks of discharge is associated with reduced readmission. The follow-up visit should include spirometry to reassess baseline function, review of inhaler technique, assessment of smoking cessation, and consideration of pulmonary rehabilitation referral. Pulmonary rehabilitation after a COPD exacerbation reduces readmission and improves quality of life.